RENALYTIX PLC LS-0025 (2O9) - Total Assets
Based on the latest financial reports, RENALYTIX PLC LS-0025 (2O9) holds total assets worth €9.90 Million EUR (≈ $11.57 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 2O9 cash generation efficiency for how efficiently the company converts equity into cash flow.
RENALYTIX PLC LS-0025 - Total Assets Trend (2022–2025)
This chart illustrates how RENALYTIX PLC LS-0025's total assets have evolved over time, based on quarterly financial data. See RENALYTIX PLC LS-0025 stock price for real-time trading data and today's change.
RENALYTIX PLC LS-0025 - Asset Composition Analysis
Current Asset Composition (June 2025)
RENALYTIX PLC LS-0025's total assets of €9.90 Million consist of 95.1% current assets and 4.9% non-current assets. Explore 2O9 working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 59.0% |
| Accounts Receivable | €600.00K | 9.8% |
| Inventory | €200.00K | 3.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how RENALYTIX PLC LS-0025's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: RENALYTIX PLC LS-0025's current assets represent 95.1% of total assets in 2025, an increase from 89.4% in 2022.
- Cash Position: Cash and equivalents constituted 59.0% of total assets in 2025, down from 82.6% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 28.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 9.8% of total assets.
RENALYTIX PLC LS-0025 Competitors by Total Assets
Key competitors of RENALYTIX PLC LS-0025 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
|
USA | $6.21 Billion |
|
Vanfund Urban Investment & Development Co Ltd
SHE:000638
|
China | CN¥228.40 Million |
|
Reliq Health Technologies Inc
V:RHT
|
Canada | CA$22.29 Million |
|
Diagnos Inc
V:ADK
|
Canada | CA$1.17 Million |
|
NexgenRX Inc.
V:NXG
|
Canada | CA$39.20 Million |
|
Careteq Ltd
AU:CTQ
|
Australia | AU$4.44 Million |
|
Oakridge International Ltd
AU:OAK
|
Australia | AU$2.12 Million |
|
Pro Medicus Ltd
AU:PME
|
Australia | AU$610.14 Million |
RENALYTIX PLC LS-0025 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.57 | 2.43 | 0.58 |
| Quick Ratio | 1.52 | 2.34 | 0.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.10 Million | €6.58 Million | €-5.00 Million |
RENALYTIX PLC LS-0025 - Advanced Valuation Insights
This section examines the relationship between RENALYTIX PLC LS-0025's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.86 |
| Latest Market Cap to Assets Ratio | 6.54 |
| Asset Growth Rate (YoY) | -14.1% |
| Total Assets | €6.10 Million |
| Market Capitalization | $39.89 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values RENALYTIX PLC LS-0025's assets at a significant premium (6.54x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: RENALYTIX PLC LS-0025's assets decreased by 14.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for RENALYTIX PLC LS-0025 (2022–2025)
The table below shows the annual total assets of RENALYTIX PLC LS-0025 from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | €6.10 Million ≈ $7.13 Million |
-14.08% |
| 2024-06-30 | €7.10 Million ≈ $8.30 Million |
-76.82% |
| 2023-06-30 | €30.63 Million ≈ $35.81 Million |
-38.82% |
| 2022-06-30 | €50.06 Million ≈ $58.53 Million |
-- |
About RENALYTIX PLC LS-0025
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more